Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 3Genitourinary 2Gastrointestinal 2Dermatologic 2Sarcoma 1Other 1Lymphoid 1Head & Neck 1CNS 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Prostatic Neoplasms 1

Interventions

Docetaxel 229Radiotherapy 206Magnetic Resonance Spectroscopy 204Radiosurgery 176Gemcitabine 155pembrolizumab 150Nivolumab 147enzalutamide 140Prednisone 129Cisplatin 123Leuprolide 119Androgen Antagonists 117Abiraterone Acetate 114Sunitinib 106Specimen Handling 94Surveys and Questionnaires 91Goserelin 91bicalutamide 90Carboplatin 88Ipilimumab 82gallium 68 PSMA-11 80Blood Specimen Collection 78Everolimus 73apalutamide 72Radiation 71Standard of Care 68Biopsy 68acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 66Paclitaxel 64Cyclophosphamide 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Rosiglitazone × Genitourinary × Clear all
NCT00084578 2013-07-15

Celecoxib and Rosiglitazone in Treating Patients Who Are Undergoing Cystoscopic Surveillance for Early-Stage Noninvasive Carcinoma of the Bladder or Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder

Fox Chase Cancer Center

Phase NA Withdrawn
Genitourinary

Urinary Bladder Neoplasms

NCT00182052 2013-05-23

Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer

Massachusetts General Hospital

Phase 3 Completed
100 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡